Yanxia Zhao

Union Hospital
Wuhan, 430023, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications

A phase II clinical trial of neoadjuvant chemotherapy combined with immunotherapy and different radiotherapy fractionation regimens in HR+/HER2- breast cancer.

A phase II clinical trial of neoadjuvant chemotherapy combined with immunotherapy and different radiotherapy fractionation regimens in HR+/HER2- breast cancer.

Journal: Frontiers in immunology
Published: March 22, 2026

Expert Consensus on the Combined Application of Radiotherapy and Novel Systemic Agents in Breast Cancer Treatment.

Expert Consensus on the Combined Application of Radiotherapy and Novel Systemic Agents in Breast Cancer Treatment.

Journal: Journal of evidence-based medicine
Published: March 04, 2026

Normalizing the Tumor Microenvironment: A New Frontier in Ovarian Cancer Therapy.

Normalizing the Tumor Microenvironment: A New Frontier in Ovarian Cancer Therapy.

Journal: International journal of molecular sciences
Published: December 03, 2025

Losartan Enhances Radiosensitivity by Reversing Immunosuppressive Tumor Microenvironment Induced by Radiotherapy in TNBC.

Losartan Enhances Radiosensitivity by Reversing Immunosuppressive Tumor Microenvironment Induced by Radiotherapy in TNBC.

Journal: Cancer science
Published: November 08, 2025

A nomogram for breast cancer brain metastasis patients after stereotactic radiotherapy.

A nomogram for breast cancer brain metastasis patients after stereotactic radiotherapy.

Journal: BMC cancer
Published: June 15, 2025

Clinical application of 90-gene expression test in a patient with occult breast cancer: a case report and literature review.

Clinical application of 90-gene expression test in a patient with occult breast cancer: a case report and literature review.

Journal: Breast cancer (Tokyo, Japan)
Published: April 04, 2025

Multiple drug resistance caused by germline mutation of exon 27 of BRCA2 gene in triple-negative breast cancer: a case report and literature review.

Multiple drug resistance caused by germline mutation of exon 27 of BRCA2 gene in triple-negative breast cancer: a case report and literature review.

Journal: Frontiers in oncology
Published: March 30, 2025

Efficacy and safety of Eribulin-based chemotherapy in HER2 negative advanced breast cancer patients: a real-world study.

Efficacy and safety of Eribulin-based chemotherapy in HER2 negative advanced breast cancer patients: a real-world study.

Journal: Frontiers in oncology
Published: September 21, 2024

Real-world comparison of palbociclib, abemaciclib, and dalpiciclib as first-line treatments for Chinese HR+/HER2-metastatic breast cancer patients: a multicenter study (YOUNGBC-28).

Real-world comparison of palbociclib, abemaciclib, and dalpiciclib as first-line treatments for Chinese HR+/HER2-metastatic breast cancer patients: a multicenter study (YOUNGBC-28).

Journal: Therapeutic advances in medical oncology
Published: August 15, 2024

Arachidonic acid triggers spermidine synthase secretion from primary tumor to induce skeletal muscle weakness upon irradiation.

Arachidonic acid triggers spermidine synthase secretion from primary tumor to induce skeletal muscle weakness upon irradiation.

Journal: Cell metabolism
Published: May 13, 2024

Losartan rewires the tumor-immune microenvironment and suppresses IGF-1 to overcome resistance to chemo-immunotherapy in ovarian cancer.

Losartan rewires the tumor-immune microenvironment and suppresses IGF-1 to overcome resistance to chemo-immunotherapy in ovarian cancer.

Journal: British journal of cancer
Published: February 05, 2024

Effectiveness and Safety of Palbociclib Plus Endocrine Therapy in Patients with Advanced Breast Cancer: A Multi-Center Study in China.

Effectiveness and Safety of Palbociclib Plus Endocrine Therapy in Patients with Advanced Breast Cancer: A Multi-Center Study in China.

Journal: Cancers
Published: July 15, 2023
Showing 1-12 of 36

Last Updated: 09/26/2026